Cellectar Biosciences, Inc. (CLRB) — 8-K Filings

8-K Filings (32)

• 8-K Filing — May 8, 2026
• Cellectar Biosciences Files 8-K on Key Corporate Events — Oct 10, 2025 Risk: medium
  Cellectar Biosciences, Inc. filed an 8-K on October 10, 2025, reporting on events as of October 7, 2025. The filing indicates the entry into a material definiti
• Cellectar Biosciences Files 8-K — Oct 6, 2025 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on October 6, 2025, reporting on various events. The filing includes information related to Regulation FD Disclosure, O
• Cellectar Biosciences Files 8-K on Operations — Aug 14, 2025 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on August 14, 2025, reporting on its results of operations and financial condition. The filing includes financial state
• Cellectar Biosciences Files 8-K: Other Event — Jun 26, 2025 Risk: medium
  Cellectar Biosciences, Inc. filed an 8-K on June 26, 2025, reporting an "Other Event." The filing does not contain specific details about the event, dollar amou
• Cellectar Biosciences Files 8-K on Security Holder Rights — Jun 25, 2025 Risk: medium
  Cellectar Biosciences, Inc. filed an 8-K on June 25, 2025, reporting material modifications to the rights of security holders and amendments to its articles of
• Cellectar Biosciences Files 8-K — Jun 18, 2025 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on June 18, 2025, reporting other events and financial statements. The company, formerly known as Novelos Therapeutics,
• Cellectar Biosciences Files 8-K on Security Holder Vote — Jun 13, 2025 Risk: medium
  Cellectar Biosciences, Inc. filed an 8-K on June 13, 2025, reporting on a submission of matters to a vote of security holders. The filing does not contain speci
• Cellectar Biosciences Files 8-K on Key Agreements & Equity Sales — Jun 5, 2025 Risk: medium
  On June 5, 2025, Cellectar Biosciences, Inc. filed an 8-K report detailing several material events. These include entering into a material definitive agreement,
• Cellectar Biosciences Files 8-K on Operations and Financials — May 13, 2025 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on May 13, 2025, reporting on its results of operations and financial condition, and including financial statements and
• Cellectar Biosciences Files 8-K — May 1, 2025 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K report on May 1, 2025, detailing events as of April 30, 2025. The filing primarily concerns financial statements and ex
• Cellectar Biosciences Reports Director/Officer Changes & Bylaw Amendments — Mar 17, 2025 Risk: medium
  Cellectar Biosciences, Inc. filed an 8-K on March 17, 2025, reporting on events that occurred on March 11, 2025. The filing indicates changes related to the dep
• Cellectar Biosciences Files 8-K on Financials — Mar 13, 2025 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on March 13, 2025, reporting on its results of operations and financial condition, and including financial statements a
• Cellectar Biosciences Faces Delisting Notice — Jan 31, 2025 Risk: high
  Cellectar Biosciences, Inc. filed an 8-K on January 31, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, and a
• Cellectar Biosciences Files 8-K — Jan 14, 2025 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on January 14, 2025, reporting events as of January 12, 2025. The filing indicates a Regulation FD Disclosure and inclu
• Cellectar Biosciences Files 8-K on Exit Costs and Disclosures — Dec 11, 2024 Risk: medium
  Cellectar Biosciences, Inc. filed an 8-K on December 10, 2024, reporting on cost associated with exit or disposal activities, Regulation FD disclosure, and othe
• Cellectar Biosciences Files 8-K on Financials — Nov 18, 2024 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on November 18, 2024, reporting on its results of operations and financial condition, and including financial statement
• Cellectar Biosciences Files 8-K — Nov 15, 2024 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on November 15, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its p
• Cellectar Biosciences Files 8-K — Nov 1, 2024 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on November 1, 2024, reporting other events and financial statements. The company, incorporated in Delaware, has its pr
• Cellectar Biosciences Faces Nasdaq Delisting Risk — Aug 23, 2024 Risk: high
  Cellectar Biosciences, Inc. received a notice on August 20, 2024, indicating it failed to meet the minimum bid price requirement for continued listing on the Na
• Cellectar Biosciences Files 8-K on Operations — Aug 13, 2024 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on August 13, 2024, reporting on its results of operations and financial condition, and including financial statements
• Cellectar Biosciences Restates Financials — Aug 9, 2024 Risk: medium
  Cellectar Biosciences, Inc. announced on August 9, 2024, that it will not rely on previously issued financial statements for the fiscal year ended December 31,
• Cellectar Biosciences to be Acquired for $10.5M — Jul 23, 2024 Risk: medium
  Cellectar Biosciences, Inc. announced on July 23, 2024, that it has entered into a definitive agreement to be acquired by an affiliate of the Pura Vida Foundati
• Cellectar Biosciences Files 8-K on Securities Purchase Agreement — Jul 22, 2024 Risk: medium
  On July 21, 2024, Cellectar Biosciences, Inc. entered into a material definitive agreement, specifically a Securities Purchase Agreement, with certain investors
• Daiichi Sankyo to Acquire Cellectar Biosciences for $31.7M — Jul 11, 2024 Risk: medium
  Cellectar Biosciences, Inc. announced on July 8, 2024, that it has entered into a definitive agreement to be acquired by a subsidiary of Daiichi Sankyo Company,
• Cellectar Biosciences Enters Material Definitive Agreement — Jun 25, 2024 Risk: medium
  Cellectar Biosciences, Inc. entered into a Material Definitive Agreement on June 20, 2024, related to a direct financial obligation. The company, incorporated i
• Cellectar Biosciences Files 8-K on Governance and Compensation — Jun 14, 2024 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on June 14, 2024, reporting on the election of directors, appointment of officers, and compensatory arrangements. The f
• Cellectar Biosciences Files 8-K on Financials — May 14, 2024 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on May 14, 2024, reporting on its results of operations and financial condition, and including financial statements and
• Cellectar Biosciences Files 8-K on Financials — Mar 27, 2024 Risk: low
  Cellectar Biosciences, Inc. filed an 8-K on March 27, 2024, reporting on its results of operations and financial condition. The filing includes financial statem
• Cellectar Biosciences Files 8-K for 'Other Event,' Signals Potential Corporate Action — Feb 2, 2024
  Cellectar Biosciences, Inc. filed an 8-K on February 2, 2024, to report an "Other Event." This filing indicates that the company is using a "Written communicati
• Cellectar Biosciences Signals Securities Communication via 8-K — Jan 25, 2024
  Cellectar Biosciences, Inc. (CLRB) filed an 8-K on January 25, 2024, indicating it is using written communications under Rule 425 of the Securities Act. This fi
• Cellectar Biosciences Confirms Nasdaq Listing for CLRB Stock — Jan 9, 2024
  Cellectar Biosciences, Inc. filed an 8-K on January 9, 2024, reporting an event that occurred on January 8, 2024. This filing indicates that the company's Commo

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX